- Current report filing (8-K)
November 24 2009 - 2:50PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
November 18,
2009
deCODE
genetics, Inc.
(Exact Name of Registrant as
Specified in Charter)
Delaware
|
|
000-30469
|
|
04-3326704
|
(State or Other Jurisdiction
|
|
(Commission
|
|
(I.R.S. Employer
|
of Incorporation)
|
|
File Number)
|
|
Identification No.)
|
Sturlugata 8, IS-101 Reykjavik,
Iceland
(Address of Principal Executive Offices)
Registrants telephone number, including area code
+354-570-1900
(Former Name or Former
Address, If Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of
the following provisions:
o
Written
communications pursuant to Rule 425 under the Securities Act
o
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act
Item 2.03. Creation of a
Direct Financial Obligation or an Obligation under an Off-Balance Sheet
Arrangement of a Registrant.
On
November 18, 2009 the U.S. Bankruptcy Court for the District of Delaware
granted interim approval of the debtor-in-possession credit agreement between
deCODE genetics, Inc. (deCODE) and Saga Investments, LLC (Saga). Following such approval, Saga advanced
$3,600,000 pursuant to the credit agreement.
Item
3.01.
Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
On November 18, 2009,
deCODE received a notice from the Nasdaq Stock Market (Nasdaq) stating that,
unless deCODE requests an appeal of the Nasdaq determination, trading in deCODEs
common stock will be suspended as of November 30, 2009 and a Form 25-NSE
will be filed with the Securities and Exchange Commission, which will remove
deCODEs common stock from listing on Nasdaq.
The Nasdaq determination was made pursuant to Nasdaq Listing Rules 5101,
5110(b) and
IM-5101-1
, which give
Nasdaq discretionary authority over the listing of securities and in particular
the discretionary authority to suspend or terminate the listing of a security
of a company that has filed for protection under the federal bankruptcy
laws. The determination was also based
on deCODEs non-compliance with Listing Rule 5250(c)(1) as result of
its failure to file its Quarterly Report on Form 10-Q for the quarter
ended September 30, 2009 as of the date of the notice.
On November 24, 2009,
deCODE appealed the determination to the Nasdaq Listing Qualifications Panel
(the Panel). Accordingly, deCODEs
common stock will continue to be listed on The Nasdaq Global Market pending the
conclusion of the appeal process. There can be no assurance that the Panel will
grant deCODEs request for continued listing.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
deCODE
genetics, Inc.
|
|
|
|
|
|
By:
|
/s/
Kari Stefansson
|
|
|
Kari
Stefansson
|
|
|
President
and Chief Executive Officer
|
|
|
|
|
Dated:
November 24, 2009
|
|
3
Decode Genetics (MM) (NASDAQ:DCGN)
Historical Stock Chart
From Oct 2024 to Nov 2024
Decode Genetics (MM) (NASDAQ:DCGN)
Historical Stock Chart
From Nov 2023 to Nov 2024